The Triumph of Innovation and the Hard Work of Caring for Patients With Diabetes
- PMID: 26641027
- DOI: 10.7326/M15-2610
The Triumph of Innovation and the Hard Work of Caring for Patients With Diabetes
Comment on
-
Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis.Ann Intern Med. 2016 Jan 19;164(2):102-13. doi: 10.7326/M15-1432. Epub 2015 Dec 8. Ann Intern Med. 2016. PMID: 26642233 Review.
Similar articles
-
Comparing once weekly GLP-1 receptor agonists for type 2 diabetes finds no clear winner.BMJ. 2015 Dec 9;351:h6702. doi: 10.1136/bmj.h6702. BMJ. 2015. PMID: 26656272 No abstract available.
-
Should GLP-1 Receptor Agonists Be the First Line of Treatment for Type 2 Diabetes?Diabetes Technol Ther. 2016 Nov;18(11):671-673. doi: 10.1089/dia.2016.0339. Diabetes Technol Ther. 2016. PMID: 27860501 No abstract available.
-
Aktuelles zur Therapie mit GLP-1-Rezeptoragonisten bei Patienten mit Diabetes mellitus Typ 2.Ther Umsch. 2017;74(8):433-439. doi: 10.1024/0040-5930/a000937. Ther Umsch. 2017. PMID: 29461151 Review. German. No abstract available.
-
Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus.Diabetes Metab Syndr. 2017 Jul-Sep;11(3):225-230. doi: 10.1016/j.dsx.2016.09.003. Epub 2016 Sep 15. Diabetes Metab Syndr. 2017. PMID: 27884496 Review.
-
GLP-1 receptor agonist confer target organ protection in type 2 diabetes.Diabetes Metab. 2017 Apr;43 Suppl 1:2S1-2S2. doi: 10.1016/S1262-3636(17)30066-6. Diabetes Metab. 2017. PMID: 28431665 No abstract available.
Cited by
-
Clinical Use of Continuous Glucose Monitoring in Adults with Type 2 Diabetes.Diabetes Technol Ther. 2017 May;19(S2):S4-S11. doi: 10.1089/dia.2017.0024. Diabetes Technol Ther. 2017. PMID: 28541137 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical